2186.HK Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 10:08):

Stats
Tagesvolumen	25.13M
Durchschnittsvolumen	9.60M
Marktkapitalisierung	10.23B
EPS	HKD0 ( 2024-03-28 )
Last Dividend	HKD0.0600 ( 2020-06-29 )
Next Dividend	HKD0 ( N/A )
P/E	18.13
ATR14	HKD0.00900 (0.33%)

Volumen Korrelation

Lang: 0.11 (neutral)

Kurz: 0.28 (neutral)

Signal:(47.09) Neutral

Luye Pharma Group Ltd Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

Luye Pharma Group Ltd Korrelation - Währung/Rohstoff

-0.38
( neutral )

-0.39
( neutral )

0.00
( neutral )

0.46
( neutral )

Luye Pharma Group Ltd Finanzdaten

Annual	2023
Umsatz:	HKD6.14B
Bruttogewinn:	HKD4.20B (68.44 %)
EPS:	HKD0.140

FY	2023
Umsatz:	HKD6.14B
Bruttogewinn:	HKD4.20B (68.44 %)
EPS:	HKD0.140

FY	2022
Umsatz:	HKD5.98B
Bruttogewinn:	HKD4.14B (69.22 %)
EPS:	HKD0.170

FY	2021
Umsatz:	HKD5.20B
Bruttogewinn:	HKD3.40B (65.32 %)
EPS:	HKD-0.0422

Financial Reports:

No articles found.

Luye Pharma Group Ltd Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

Luye Pharma Group Ltd Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 8.62 - good (86.18%) | Divividend Growth Potential Score: 4.10 - Potential for dividend initiation, but uncertain (18.00%)

Information

First Dividend	HKD0.0370	2016-10-04
Last Dividend	HKD0.0600	2020-06-29
Next Dividend	HKD0	N/A
Payout Date	2020-07-24
Next Payout Date	N/A
# dividends	8	--
Total Paid Out	HKD0.406	--
Avg. Dividend % Per Year	0.00%	--
Score	2.99	--
Div. Sustainability Score	8.62
Div.Growth Potential Score	4.10
Div. Directional Score	6.36	--

Next Divdend (Est)
(2024-08-02)

HKD0 Estimate 0.00 %

Dividend Stability

0.06 Very Bad

Dividend Score

2.99

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
9997.HK	Ex Dividend Knight	2023-05-30	Annually	0.00%
2202.HK	Ex Dividend Junior	2023-07-14	Annually	0.00%
1209.HK	Ex Dividend Knight	2023-09-12	Semi-Annually	0.00%
0288.HK	Ex Dividend Knight	2023-08-28	Semi-Annually	0.00%
3968.HK	Ex Dividend Knight	2023-07-05	Annually	0.00%
1786.HK	Ex Dividend Junior	2023-07-04	Sporadic	0.00%
0822.HK	Ex Dividend Junior	2023-06-05	Annually	0.00%
2362.HK	No Dividend Player	2023-06-01	Annually	0.00%
1349.HK	Ex Dividend Junior	2023-06-05	Annually	0.00%
0393.HK	Ex Dividend Knight	2023-09-14	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0867	1.500	8.27	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0209	1.200	9.30	10.00	[0 - 0.3]
returnOnEquityTTM	0.0446	1.500	-0.615	-0.923	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.315	0.800	8.42	6.74	[1 - 3]
quickRatioTTM	0.844	0.800	9.74	7.79	[0.8 - 2.5]
cashRatioTTM	0.398	1.500	8.90	10.00	[0.2 - 2]
debtRatioTTM	0.330	-1.500	4.50	-6.76	[0 - 0.6]
interestCoverageTTM	2.56	1.000	-0.164	-0.164	[3 - 30]
operatingCashFlowPerShareTTM	0.183	2.00	9.94	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.0387	2.00	9.98	10.00	[0 - 20]
debtEquityRatioTTM	0.671	-1.500	7.32	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.684	1.000	1.927	1.927	[0.2 - 0.8]
operatingProfitMarginTTM	0.144	1.000	9.11	9.11	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.0821	1.000	-0.655	-0.655	[0.2 - 2]
assetTurnoverTTM	0.241	0.800	-1.727	-1.381	[0.5 - 2]
Total Score				8.62

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	17.77	1.000	8.31	0	[1 - 100]
returnOnEquityTTM	0.0446	2.50	-0.395	-0.923	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.0387	2.00	9.99	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.183	2.00	9.94	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	1.601	1.500	2.66	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.112	1.000	9.69	0	[0.1 - 0.5]
Total Score				4.10

Luye Pharma Group Ltd

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders, In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sailimai for the treatment of diarrhea; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.